The 4 most recent market catalysts affecting $ANRO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55
HC Wainwright & Co. analyst Patrick R. Trucchio maintained a 'Buy' rating on Alto Neuroscience (ANRO) and raised the price target from $50 to $55. This analyst upgrade signals incr…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37
BTIG analyst Thomas Shrader maintained a 'Buy' rating on Alto Neuroscience (ANRO) and raised the price target from $28 to $37. This action signals increased confidence from a reput…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 75
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
Alto Neuroscience (ANRO) announced its Q2 earnings, reporting a loss of $(0.65) per share. This figure 'beat' the consensus analyst estimate of a $(0.73) loss by 10.96%. While stil…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 75
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/Share
Alto Neuroscience has priced an underwritten registered direct offering of 3.776 million common shares at $26.48 per share, aiming to raise approximately $100 million. This capital…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.